Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LIBERTY LAKE, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vega Cloud unveiled its latest offering, Vega Datametry, today at AWS re:Invent 2023. Built on the Vega Cloud Platform, the solution is...
-
BELLEVUE, Wash., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Appen Limited (ASX:APX), a leading provider of high-quality data for the AI lifecycle, has selected Amazon Web Services (AWS) as its primary cloud...
-
Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to date...
-
HERNDON, Va., Nov. 16, 2023 (GLOBE NEWSWIRE) -- SMX, a leader in next-generation mission support, digital transformation and IT solutions, today announced the acquisition of Outside Analytics (OA),...
-
OTTAWA, ON CANADA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Recollective Inc. Introduces Brand Update Emphasizing The Qualitative Research Platform That Helps Researchers Do Their Research, Their Way ...
-
Data Science Salon is set to launch in San Francisco on November 29, 2023 at Dogpatch Studios, highlighting its focus on Generative AI, Data Science and ML
-
CHARLOTTE, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Capstone Technologies Group Inc (OTC: CATG), a leading acquirer, operator and organic developer of disruptive technologies, today announced the...
-
Cintas Corporation and Lemongrass Complete Major SAP Migration to Google Cloud with Minimal Downtime
ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Lemongrass, a software-enabled services provider synonymous with SAP on Cloud, announces the completion of a year-long project in which it assisted Cintas...
-
Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and...
-
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary...